Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05569408 · ClinicalTrials.gov registry record
eVusheld Assessment reaL wORld Effectiveness in DoD Health System
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 4,724
- Enrollment target
NCT05569408: Completed study, sponsored by AstraZeneca.
NCT05569408 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 4,724 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05569408 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 4,724 participants
- Enrollment target
Study Summary
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population treated in DoD Health system.
Primary Outcome
To assess the effectiveness of EVUSHELD as PrEP against COVID-19 hospitalizations up to 6 months following its initial administration
Interventions
- DRUG EVUSHELD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,724 participants |
| Start Date | 2023-08-10 |
| Est. Completion | 2023-12-22 |
What the finished NCT05569408 record still lists
NCT05569408 is an observational study that tracks outcomes without assigning an intervention. Its 4,724 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which EVUSHELD is the first listed.
NCT05569408 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05569408 about?
NCT05569408 is a clinical study titled "eVusheld Assessment reaL wORld Effectiveness in DoD Health System". An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient popu...
What is the current status of trial NCT05569408?
This trial is currently completed. The enrollment target is 4,724 participants. The study started on 2023-08-10. Estimated completion is 2023-12-22.
What interventions are being tested in trial NCT05569408?
The interventions under investigation include: EVUSHELD (DRUG).
Who is sponsoring clinical trial NCT05569408?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04371900 · 4,700 participants · NA
Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1
- NCT05486572 · 4,700 participants · NA
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- NCT06888388 · 4,700 participants
Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI